{"transactions":[{"id":4629678,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-05T20:03:34.000Z","date":"2026-10-01","kind":"sale","planned":false,"acquired":false,"shares":11767,"price":2.8604,"value":33658.3268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 64,418 shares represent restricted stock units."}],"balance_after":155983,"source":{"system":"sec-edgar","filing":"0001501697-26-000078","document":"wk-form4_1791230611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000078/wk-form4_1791230611.xml","form_type":"4"}},{"id":687773,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23643,"kind":"person","name":"Volpone John","position":1,"cik":"0002081729","reported_name":"Volpone John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-08-13T20:13:03.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":24576,"price":4.4445,"value":109228.032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported,  193,254 shares represent restricted stock units."}],"balance_after":265305,"source":{"system":"sec-edgar","filing":"0001501697-26-000070","document":"wk-form4_1786651978.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000070/wk-form4_1786651978.xml","form_type":"4"}},{"id":687797,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-08-13T20:10:23.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":47436,"price":4.4445,"value":210829.302,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33  to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 193,254 shares represent restricted stock units."}],"balance_after":328651,"source":{"system":"sec-edgar","filing":"0001501697-26-000069","document":"wk-form4_1786651821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000150169726000069/wk-form4_1786651821.xml","form_type":"4"}},{"id":720851,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:23:25.000Z","date":"2026-06-30","kind":"sale","planned":false,"acquired":false,"shares":8543,"price":4.2641,"value":36428.2063,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.21 to $4.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 96,627 shares represent restricted stock units."}],"balance_after":167750,"source":{"system":"sec-edgar","filing":"0001501697-26-000065","document":"wk-form4_1782937402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000150169726000065/wk-form4_1782937402.xml","form_type":"4"}},{"id":721579,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":1162,"kind":"person","name":"Gold Kelly","position":1,"cik":"0002033333","reported_name":"Gold Kelly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T20:20:10.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date."}],"balance_after":110000,"derivative":{"exercise_price":4.085,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001501697-26-000064","document":"wk-form4_1782937206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033333/000150169726000064/wk-form4_1782937206.xml","form_type":"4"}},{"id":780547,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-13T20:02:44.000Z","date":"2026-05-12","kind":"sale","planned":false,"acquired":false,"shares":16961,"price":4.2934,"value":72820.3574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.20 to $4.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 128,836 shares represent restricted stock units."}],"balance_after":176293,"source":{"system":"sec-edgar","filing":"0001501697-26-000049","document":"wk-form4_1778702561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000150169726000049/wk-form4_1778702561.xml","form_type":"4"}},{"id":944084,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":69829,"kind":"person","name":"Bridger Gary","position":1,"cik":"0001600049","reported_name":"Bridger Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T21:00:12.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date."}],"balance_after":0,"derivative":{"exercise_price":4,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001501697-26-000009","document":"wk-form4_1767819605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000009/wk-form4_1767819605.xml","form_type":"4"}},{"id":950389,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":70268,"kind":"person","name":"de Craecker Francoise","position":1,"cik":"0001887843","reported_name":"de Craecker Francoise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:06:13.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date."}],"balance_after":0,"derivative":{"exercise_price":4,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001501697-26-000007","document":"wk-form4_1767647168.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000007/wk-form4_1767647168.xml","form_type":"4"}},{"id":950564,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:05:30.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date."}],"balance_after":0,"derivative":{"exercise_price":4,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001501697-26-000006","document":"wk-form4_1767647121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000150169726000006/wk-form4_1767647121.xml","form_type":"4"}},{"id":950387,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":38523,"kind":"person","name":"Stewart Murray","position":1,"cik":"0001723450","reported_name":"Stewart Murray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:04:43.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date."}],"balance_after":0,"derivative":{"exercise_price":4,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001501697-26-000005","document":"wk-form4_1767647080.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000005/wk-form4_1767647080.xml","form_type":"4"}},{"id":1010466,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-31T20:42:05.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":2329154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":2329154,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":2329154},"source":{"system":"sec-edgar","filing":"0001339498-25-000004","document":"wk-form4_1761943322.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000133949825000004/wk-form4_1761943322.xml","form_type":"4"}},{"id":1010454,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23643,"kind":"person","name":"Volpone John","position":1,"cik":"0002081729","reported_name":"Volpone John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-31T20:41:59.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":2329154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":2329154,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":2329154},"source":{"system":"sec-edgar","filing":"0002081729-25-000003","document":"wk-form4_1761943317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000208172925000003/wk-form4_1761943317.xml","form_type":"4"}},{"id":1010467,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-31T20:41:55.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":1552769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":1552769,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":1552769},"source":{"system":"sec-edgar","filing":"0001276750-25-000004","document":"wk-form4_1761943312.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000127675025000004/wk-form4_1761943312.xml","form_type":"4"}},{"id":1013117,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-10-27T22:40:40.000Z","date":"2025-10-23","kind":"purchase","planned":false,"acquired":true,"shares":86206,"price":2.9,"value":249997.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of the Issuer's common stock purchased in connection with the Issuer's public offering."}],"balance_after":376087,"source":{"system":"sec-edgar","filing":"0001501697-25-000035","document":"wk-form4_1761604837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000150169725000035/wk-form4_1761604837.xml","form_type":"4"}},{"id":1066158,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23643,"kind":"person","name":"Volpone John","position":1,"cik":"0002081729","reported_name":"Volpone John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:46.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":529201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":529201,"derivative":{"exercise_price":3.14,"expiration_date":"2035-08-14","underlying":"Common Stock","underlying_shares":529201},"source":{"system":"sec-edgar","filing":"0001628280-25-040444","document":"wk-form4_1755217902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025040444/wk-form4_1755217902.xml","form_type":"4"}},{"id":1066157,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23643,"kind":"person","name":"Volpone John","position":1,"cik":"0002081729","reported_name":"Volpone John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:46.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":1609873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":1609873,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":1609873},"source":{"system":"sec-edgar","filing":"0001628280-25-040444","document":"wk-form4_1755217902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025040444/wk-form4_1755217902.xml","form_type":"4"}},{"id":1066156,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23643,"kind":"person","name":"Volpone John","position":1,"cik":"0002081729","reported_name":"Volpone John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-08-15T00:31:46.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":289881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders."}],"balance_after":289881,"source":{"system":"sec-edgar","filing":"0001628280-25-040444","document":"wk-form4_1755217902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025040444/wk-form4_1755217902.xml","form_type":"4"}},{"id":1066209,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:21.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":529201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":529201,"derivative":{"exercise_price":3.14,"expiration_date":"2035-08-14","underlying":"Common Stock","underlying_shares":529201},"source":{"system":"sec-edgar","filing":"0001628280-25-040441","document":"wk-form4_1755217877.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000162828025040441/wk-form4_1755217877.xml","form_type":"4"}},{"id":1066208,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:21.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":1609873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":1609873,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":1609873},"source":{"system":"sec-edgar","filing":"0001628280-25-040441","document":"wk-form4_1755217877.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000162828025040441/wk-form4_1755217877.xml","form_type":"4"}},{"id":1066207,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-08-15T00:31:21.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":289881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders."}],"balance_after":289881,"source":{"system":"sec-edgar","filing":"0001628280-25-040441","document":"wk-form4_1755217877.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000162828025040441/wk-form4_1755217877.xml","form_type":"4"}},{"id":1066227,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:14.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":352800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to\nthe Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based\nmilestones prior to February 12, 2026."}],"balance_after":352800,"derivative":{"exercise_price":3.14,"expiration_date":"2035-08-14","underlying":"Common Stock","underlying_shares":352800},"source":{"system":"sec-edgar","filing":"0001628280-25-040440","document":"wk-form4_1755217870.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000162828025040440/wk-form4_1755217870.xml","form_type":"4"}},{"id":1066226,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:14.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":1073249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to\nthe Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based\nmilestones prior to February 12, 2026."}],"balance_after":1073249,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":1073249},"source":{"system":"sec-edgar","filing":"0001628280-25-040440","document":"wk-form4_1755217870.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000162828025040440/wk-form4_1755217870.xml","form_type":"4"}},{"id":1066225,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":33860,"kind":"person","name":"KIRSKE DAVID","position":1,"cik":"0001276750","reported_name":"KIRSKE DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-15T00:31:14.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":193254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive quarter thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders."}],"balance_after":193254,"source":{"system":"sec-edgar","filing":"0001628280-25-040440","document":"wk-form4_1755217870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1276750/000162828025040440/wk-form4_1755217870.xml","form_type":"4"}},{"id":1092901,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":77732,"kind":"person","name":"Thoren Natasha Fay","position":1,"cik":"0002070977","reported_name":"Thoren Natasha Fay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-07-03T16:21:11.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on  May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025."}],"balance_after":9462,"source":{"system":"sec-edgar","filing":"0001628280-25-034233","document":"wk-form4_1751574063.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2070977/000162828025034233/wk-form4_1751574063.xml","form_type":"4"}},{"id":1116041,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":38523,"kind":"person","name":"Stewart Murray","position":1,"cik":"0001723450","reported_name":"Stewart Murray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T20:30:52.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":7883,"source":{"system":"sec-edgar","filing":"0001628280-25-030504","document":"wk-form4_1749587446.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025030504/wk-form4_1749587446.xml","form_type":"4"}},{"id":1116040,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":70268,"kind":"person","name":"de Craecker Francoise","position":1,"cik":"0001887843","reported_name":"de Craecker Francoise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T20:30:44.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":4722,"source":{"system":"sec-edgar","filing":"0001628280-25-030503","document":"wk-form4_1749587436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025030503/wk-form4_1749587436.xml","form_type":"4"}},{"id":1116039,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":69829,"kind":"person","name":"Bridger Gary","position":1,"cik":"0001600049","reported_name":"Bridger Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T20:30:32.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":4722,"source":{"system":"sec-edgar","filing":"0001628280-25-030502","document":"wk-form4_1749587426.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025030502/wk-form4_1749587426.xml","form_type":"4"}},{"id":1116038,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T20:30:21.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001628280-25-030500","document":"wk-form4_1749587415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025030500/wk-form4_1749587415.xml","form_type":"4"}},{"id":1116129,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":35343,"kind":"person","name":"MCGIRR DAVID W J","position":1,"cik":"0001219023","reported_name":"MCGIRR DAVID W J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T20:28:20.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":4722,"source":{"system":"sec-edgar","filing":"0001628280-25-030492","document":"wk-form4_1749587293.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219023/000162828025030492/wk-form4_1749587293.xml","form_type":"4"}},{"id":1116135,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T20:25:25.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":5555,"source":{"system":"sec-edgar","filing":"0001628280-25-030489","document":"wk-form4_1749587118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828025030489/wk-form4_1749587118.xml","form_type":"4"}},{"id":1124383,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-06-03T21:01:06.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":1032,"price":2.482,"value":2561.424,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":25337,"source":{"system":"sec-edgar","filing":"0001628280-25-029113","document":"wk-form4a_1748984454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025029113/wk-form4a_1748984454.xml","form_type":"4/A","original_submission_date":"2025-05-20"}},{"id":1140117,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T20:51:03.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":1032,"price":2.482,"value":2561.424,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share."}],"balance_after":25337,"source":{"system":"sec-edgar","filing":"0001628280-25-026864","document":"wk-form4_1747774254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025026864/wk-form4_1747774254.xml","form_type":"4"}},{"id":1266830,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":74547,"kind":"person","name":"Arbet-Engels Christophe","position":1,"cik":"0001802615","reported_name":"Arbet-Engels Christophe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:09:09.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":864207,"source":{"system":"sec-edgar","filing":"0001628280-25-005704","document":"wk-form4_1739567336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005704/wk-form4_1739567336.xml","form_type":"4"}},{"id":1266829,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-14T21:08:38.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":2250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":3337386,"source":{"system":"sec-edgar","filing":"0001628280-25-005700","document":"wk-form4_1739567310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005700/wk-form4_1739567310.xml","form_type":"4"}},{"id":1266828,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:08:25.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":729173,"source":{"system":"sec-edgar","filing":"0001628280-25-005698","document":"wk-form4_1739567298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005698/wk-form4_1739567298.xml","form_type":"4"}},{"id":1266827,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:08:25.000Z","date":"2024-11-15","kind":"purchase","planned":false,"acquired":true,"shares":13404,"price":0.343,"value":4597.572,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported."}],"balance_after":129173,"source":{"system":"sec-edgar","filing":"0001628280-25-005698","document":"wk-form4_1739567298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005698/wk-form4_1739567298.xml","form_type":"4"}},{"id":1266826,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:08:25.000Z","date":"2024-05-17","kind":"purchase","planned":false,"acquired":true,"shares":21646,"price":0.677,"value":14654.342,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported."}],"balance_after":115769,"source":{"system":"sec-edgar","filing":"0001628280-25-005698","document":"wk-form4_1739567298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005698/wk-form4_1739567298.xml","form_type":"4"}},{"id":1267390,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T16:08:54.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":850000,"source":{"system":"sec-edgar","filing":"0001628280-25-005702","document":"wk-form4_1739567322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828025005702/wk-form4_1739567322.xml","form_type":"4"}},{"id":1267635,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-14T16:08:16.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":1140980,"source":{"system":"sec-edgar","filing":"0001628280-25-005696","document":"wk-form4_1739567286.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828025005696/wk-form4_1739567286.xml","form_type":"4"}},{"id":1294302,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:54.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":76473,"price":0.454,"value":34718.742,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4468 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1087386,"source":{"system":"sec-edgar","filing":"0001628280-25-002709","document":"wk-form4_1738019748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002709/wk-form4_1738019748.xml","form_type":"4"}},{"id":1294301,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:54.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":169940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":1163859,"source":{"system":"sec-edgar","filing":"0001628280-25-002709","document":"wk-form4_1738019748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002709/wk-form4_1738019748.xml","form_type":"4"}},{"id":1294304,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:32.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":29159,"price":0.4541,"value":13241.1019,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4475 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":94123,"source":{"system":"sec-edgar","filing":"0001628280-25-002707","document":"wk-form4_1738019726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002707/wk-form4_1738019726.xml","form_type":"4"}},{"id":1294303,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:32.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":74773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":123282,"source":{"system":"sec-edgar","filing":"0001628280-25-002707","document":"wk-form4_1738019726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002707/wk-form4_1738019726.xml","form_type":"4"}},{"id":1294300,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":74547,"kind":"person","name":"Arbet-Engels Christophe","position":1,"cik":"0001802615","reported_name":"Arbet-Engels Christophe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:12.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":11624,"price":0.4546,"value":5284.2704,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4478 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14207,"source":{"system":"sec-edgar","filing":"0001628280-25-002705","document":"wk-form4_1738019705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002705/wk-form4_1738019705.xml","form_type":"4"}},{"id":1294299,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":74547,"kind":"person","name":"Arbet-Engels Christophe","position":1,"cik":"0001802615","reported_name":"Arbet-Engels Christophe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:12.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":25831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":25831,"source":{"system":"sec-edgar","filing":"0001628280-25-002705","document":"wk-form4_1738019705.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002705/wk-form4_1738019705.xml","form_type":"4"}},{"id":1294514,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:43.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":74773,"price":0.454,"value":33946.942,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.447 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-25-002708","document":"wk-form4_1738019736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828025002708/wk-form4_1738019736.xml","form_type":"4"}},{"id":1294513,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:43.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":74773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":74773,"source":{"system":"sec-edgar","filing":"0001628280-25-002708","document":"wk-form4_1738019736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828025002708/wk-form4_1738019736.xml","form_type":"4"}},{"id":1294596,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:24.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":22258,"price":0.4535,"value":10094.003,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4472 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":490980,"source":{"system":"sec-edgar","filing":"0001628280-25-002706","document":"wk-form4_1738019716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828025002706/wk-form4_1738019716.xml","form_type":"4"}},{"id":1294595,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:24.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":61178,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":513238,"source":{"system":"sec-edgar","filing":"0001628280-25-002706","document":"wk-form4_1738019716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828025002706/wk-form4_1738019716.xml","form_type":"4"}},{"id":1358528,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-19T21:31:25.000Z","date":"2024-11-15","kind":"sale","planned":false,"acquired":false,"shares":31897,"price":0.3945,"value":12583.3665,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.364 to $0.41, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":993919,"source":{"system":"sec-edgar","filing":"0001628280-24-048467","document":"wk-form4_1732051877.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024048467/wk-form4_1732051877.xml","form_type":"4"}},{"id":1385721,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-16T20:54:43.000Z","date":"2024-10-15","kind":"sale","planned":false,"acquired":false,"shares":31897,"price":0.562,"value":17926.114,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5424 to $0.5806, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1025816,"source":{"system":"sec-edgar","filing":"0001628280-24-042941","document":"wk-form4_1729112077.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042941/wk-form4_1729112077.xml","form_type":"4"}},{"id":1389170,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:32.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":11127,"price":0.5847,"value":6505.9569,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.561 to $0.6115, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":48509,"source":{"system":"sec-edgar","filing":"0001628280-24-042544","document":"wk-form4_1728420266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042544/wk-form4_1728420266.xml","form_type":"4"}},{"id":1389169,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:32.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":34946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition."}],"balance_after":59636,"source":{"system":"sec-edgar","filing":"0001628280-24-042544","document":"wk-form4_1728420266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042544/wk-form4_1728420266.xml","form_type":"4"}},{"id":1389168,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:23.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":239436,"price":0.5493,"value":131522.1948,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5142 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1057713,"source":{"system":"sec-edgar","filing":"0001628280-24-042543","document":"wk-form4_1728420257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042543/wk-form4_1728420257.xml","form_type":"4"}},{"id":1389167,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:23.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":532081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition."}],"balance_after":1297149,"source":{"system":"sec-edgar","filing":"0001628280-24-042543","document":"wk-form4_1728420257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042543/wk-form4_1728420257.xml","form_type":"4"}},{"id":1389166,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:02.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":76920,"price":0.563,"value":43305.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5291 to $0.6038, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":388026,"source":{"system":"sec-edgar","filing":"0001628280-24-042541","document":"wk-form4_1728420235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042541/wk-form4_1728420235.xml","form_type":"4"}},{"id":1389165,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:02.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition."}],"balance_after":464946,"source":{"system":"sec-edgar","filing":"0001628280-24-042541","document":"wk-form4_1728420235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042541/wk-form4_1728420235.xml","form_type":"4"}},{"id":1389365,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:42.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":230645,"price":0.5502,"value":126900.879,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5144 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-24-042545","document":"wk-form4_1728420276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024042545/wk-form4_1728420276.xml","form_type":"4"}},{"id":1389364,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:42.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of the performance condition."}],"balance_after":230645,"source":{"system":"sec-edgar","filing":"0001628280-24-042545","document":"wk-form4_1728420276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024042545/wk-form4_1728420276.xml","form_type":"4"}},{"id":1389424,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:13.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":67695,"price":0.5662,"value":38328.909,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.55  to $0.6043, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":452060,"source":{"system":"sec-edgar","filing":"0001628280-24-042542","document":"wk-form4_1728420247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024042542/wk-form4_1728420247.xml","form_type":"4"}},{"id":1389423,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:13.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition."}],"balance_after":519755,"source":{"system":"sec-edgar","filing":"0001628280-24-042542","document":"wk-form4_1728420247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024042542/wk-form4_1728420247.xml","form_type":"4"}},{"id":1409886,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-09-11T16:01:29.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":2642,"price":0.6577,"value":1737.6434,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.6548 to $0.6646, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":289110,"source":{"system":"sec-edgar","filing":"0001628280-24-040128","document":"wk-form4_1726084882.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024040128/wk-form4_1726084882.xml","form_type":"4"}},{"id":1483095,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":70268,"kind":"person","name":"de Craecker Francoise","position":1,"cik":"0001887843","reported_name":"de Craecker Francoise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:13:35.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":96667,"source":{"system":"sec-edgar","filing":"0001628280-24-027678","document":"wk-form4_1718136807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024027678/wk-form4_1718136807.xml","form_type":"4"}},{"id":1483094,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":90042,"kind":"person","name":"Aliski William","position":1,"cik":"0001598426","reported_name":"Aliski William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:13:25.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":96667,"source":{"system":"sec-edgar","filing":"0001628280-24-027677","document":"wk-form4_1718136796.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024027677/wk-form4_1718136796.xml","form_type":"4"}},{"id":1483175,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":35343,"kind":"person","name":"MCGIRR DAVID W J","position":1,"cik":"0001219023","reported_name":"MCGIRR DAVID W J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:13:13.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":96667,"source":{"system":"sec-edgar","filing":"0001628280-24-027676","document":"wk-form4_1718136785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219023/000162828024027676/wk-form4_1718136785.xml","form_type":"4"}},{"id":1483093,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":38523,"kind":"person","name":"Stewart Murray","position":1,"cik":"0001723450","reported_name":"Stewart Murray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:13:02.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":191504,"source":{"system":"sec-edgar","filing":"0001628280-24-027675","document":"wk-form4_1718136772.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024027675/wk-form4_1718136772.xml","form_type":"4"}},{"id":1483092,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":69829,"kind":"person","name":"Bridger Gary","position":1,"cik":"0001600049","reported_name":"Bridger Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:12:48.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":96667,"source":{"system":"sec-edgar","filing":"0001628280-24-027674","document":"wk-form4_1718136760.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024027674/wk-form4_1718136760.xml","form_type":"4"}},{"id":1483091,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:12:38.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":135000,"source":{"system":"sec-edgar","filing":"0001628280-24-027673","document":"wk-form4_1718136748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024027673/wk-form4_1718136748.xml","form_type":"4"}},{"id":1483089,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":44738,"kind":"person","name":"Lawton Alison Frances","position":1,"cik":"0001542650","reported_name":"Lawton Alison Frances","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:12:24.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":96667,"source":{"system":"sec-edgar","filing":"0001628280-24-027672","document":"wk-form4_1718136736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024027672/wk-form4_1718136736.xml","form_type":"4"}},{"id":1483180,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:12:12.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer."}],"balance_after":121667,"source":{"system":"sec-edgar","filing":"0001628280-24-027671","document":"wk-form4_1718136724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828024027671/wk-form4_1718136724.xml","form_type":"4"}},{"id":1583719,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-11T21:20:25.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":14235,"price":0.8818,"value":12552.423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9112, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":234301,"source":{"system":"sec-edgar","filing":"0001628280-24-010281","document":"wk-form4_1710192010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024010281/wk-form4_1710192010.xml","form_type":"4"}},{"id":1583718,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-11T21:20:09.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":49678,"price":0.8828,"value":43855.7384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":765068,"source":{"system":"sec-edgar","filing":"0001628280-24-010280","document":"wk-form4_1710191995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024010280/wk-form4_1710191995.xml","form_type":"4"}},{"id":1584288,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T17:19:52.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":52500,"price":0.8828,"value":46347.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.8649 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-24-010279","document":"wk-form4_1710191979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024010279/wk-form4_1710191979.xml","form_type":"4"}},{"id":1584529,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-03-11T17:19:38.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":15409,"price":0.882,"value":13590.738,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":291752,"source":{"system":"sec-edgar","filing":"0001628280-24-010278","document":"wk-form4_1710191967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024010278/wk-form4_1710191967.xml","form_type":"4"}},{"id":1611808,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":74547,"kind":"person","name":"Arbet-Engels Christophe","position":1,"cik":"0001802615","reported_name":"Arbet-Engels Christophe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-28T22:52:37.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":180816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 amendment is being filed to correct the number of stock appreciation rights awarded to the Reporting Person on February 13, 2024. The original Form 4 filed on February 16, 2024 inadvertently reported the number of stock appreciation rights awarded as 475,831 due to an administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":180816,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":180816},"source":{"system":"sec-edgar","filing":"0001628280-24-007711","document":"wk-form4a_1709160742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024007711/wk-form4a_1709160742.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1637699,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":74547,"kind":"person","name":"Arbet-Engels Christophe","position":1,"cik":"0001802615","reported_name":"Arbet-Engels Christophe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T22:11:27.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":475831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an\nemployee of the Issuer through and including each applicable vesting date."}],"balance_after":475831,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":475831},"source":{"system":"sec-edgar","filing":"0001628280-24-005385","document":"wk-form4_1708121451.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024005385/wk-form4_1708121451.xml","form_type":"4"}},{"id":1637698,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T22:09:27.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":1189578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":1189578,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":1189578},"source":{"system":"sec-edgar","filing":"0001628280-24-005382","document":"wk-form4_1708121356.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024005382/wk-form4_1708121356.xml","form_type":"4"}},{"id":1637697,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T22:09:15.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":523414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an\nemployee of the Issuer through and including each applicable vesting date."}],"balance_after":523414,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":523414},"source":{"system":"sec-edgar","filing":"0001628280-24-005380","document":"wk-form4_1708121338.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024005380/wk-form4_1708121338.xml","form_type":"4"}},{"id":1637696,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T22:08:51.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":428248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":428248,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":428248},"source":{"system":"sec-edgar","filing":"0001628280-24-005379","document":"wk-form4_1708121312.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024005379/wk-form4_1708121312.xml","form_type":"4"}},{"id":1638339,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T17:10:00.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":523414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":523414,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":523414},"source":{"system":"sec-edgar","filing":"0001628280-24-005384","document":"wk-form4_1708121388.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024005384/wk-form4_1708121388.xml","form_type":"4"}},{"id":1638589,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T17:09:45.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":428248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":428248,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":428248},"source":{"system":"sec-edgar","filing":"0001628280-24-005383","document":"wk-form4_1708121369.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024005383/wk-form4_1708121369.xml","form_type":"4"}},{"id":1648828,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-12T22:23:28.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":787,"price":1.0072,"value":792.6664,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":248536,"source":{"system":"sec-edgar","filing":"0001628280-24-004287","document":"wk-form4_1707776584.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024004287/wk-form4_1707776584.xml","form_type":"4"}},{"id":1648827,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-12T22:05:01.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":21695,"price":1.0091,"value":21892.4245,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":814746,"source":{"system":"sec-edgar","filing":"0001628280-24-004266","document":"wk-form4_1707775482.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024004266/wk-form4_1707775482.xml","form_type":"4"}},{"id":1649550,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-12T17:23:55.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":3683,"price":1.007,"value":3708.781,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":307161,"source":{"system":"sec-edgar","filing":"0001628280-24-004288","document":"wk-form4_1707776621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828024004288/wk-form4_1707776621.xml","form_type":"4"}},{"id":1649385,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-12T17:03:58.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":27721,"price":1.0091,"value":27973.2611,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.07, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":52500,"source":{"system":"sec-edgar","filing":"0001628280-24-004263","document":"wk-form4_1707775417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024004263/wk-form4_1707775417.xml","form_type":"4"}},{"id":1749421,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-11-03T21:26:49.000Z","date":"2023-11-03","kind":"sale","planned":true,"acquired":false,"shares":39906,"price":0.9,"value":35915.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8043 to $0.9454, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":836441,"source":{"system":"sec-edgar","filing":"0001628280-23-036796","document":"wk-form4_1699046800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036796/wk-form4_1699046800.xml","form_type":"4"}},{"id":1749420,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-11-03T21:26:49.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":199531,"price":0.73,"value":145657.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":876347,"source":{"system":"sec-edgar","filing":"0001628280-23-036796","document":"wk-form4_1699046800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036796/wk-form4_1699046800.xml","form_type":"4"}},{"id":1749419,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-11-03T20:39:45.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":10257,"price":0.73,"value":7487.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.687 to $0.7927, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":24690,"source":{"system":"sec-edgar","filing":"0001628280-23-036756","document":"wk-form4_1699043973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036756/wk-form4_1699043973.xml","form_type":"4"}},{"id":1749418,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-03T20:39:14.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":67695,"price":0.73,"value":49417.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6841 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":249323,"source":{"system":"sec-edgar","filing":"0001628280-23-036755","document":"wk-form4_1699043942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036755/wk-form4_1699043942.xml","form_type":"4"}},{"id":1749885,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-03T16:42:15.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":230645,"price":0.73,"value":168370.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.7911, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":80221,"source":{"system":"sec-edgar","filing":"0001628280-23-036758","document":"wk-form4_1699044122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023036758/wk-form4_1699044122.xml","form_type":"4"}},{"id":1750031,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-11-03T16:40:51.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":67695,"price":0.73,"value":49417.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6839 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":310844,"source":{"system":"sec-edgar","filing":"0001628280-23-036757","document":"wk-form4_1699044035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023036757/wk-form4_1699044035.xml","form_type":"4"}},{"id":1751079,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-11-02T21:00:56.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":34947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":34947,"source":{"system":"sec-edgar","filing":"0001628280-23-036466","document":"wk-form4_1698958841.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036466/wk-form4_1698958841.xml","form_type":"4"}},{"id":1751077,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-02T20:59:02.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":317018,"source":{"system":"sec-edgar","filing":"0001628280-23-036463","document":"wk-form4_1698958731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036463/wk-form4_1698958731.xml","form_type":"4"}},{"id":1751078,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78029,"kind":"person","name":"Ragan Paula","position":1,"cik":"0001769914","reported_name":"Ragan Paula","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-11-02T20:58:23.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":532081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":1075878,"source":{"system":"sec-edgar","filing":"0001628280-23-036462","document":"wk-form4_1698958692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036462/wk-form4_1698958692.xml","form_type":"4"}},{"id":1751419,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-02T17:04:31.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":310866,"source":{"system":"sec-edgar","filing":"0001628280-23-036471","document":"wk-form4_1698959058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023036471/wk-form4_1698959058.xml","form_type":"4"}},{"id":1751484,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-11-02T16:55:34.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":378539,"source":{"system":"sec-edgar","filing":"0001628280-23-036459","document":"wk-form4_1698958524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023036459/wk-form4_1698958524.xml","form_type":"4"}},{"id":1757971,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-18T20:02:34.000Z","date":"2023-10-16","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock units (\"RSUs\") grant.  The RSUs will vest in three equal annual installments commencing on October 16, 2024, subject to the Reporting Person's continued service as a director through each such date."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001628280-23-034579","document":"wk-form4_1697659344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023034579/wk-form4_1697659344.xml","form_type":"4"}},{"id":1783098,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83200,"kind":"person","name":"DiBiase Mary","position":1,"cik":"0001880179","reported_name":"DiBiase Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-09-12T16:04:56.000Z","date":"2023-09-08","kind":"sale","planned":false,"acquired":false,"shares":2642,"price":1.249,"value":3299.858,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.22 to $1.255, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 74,046 shares represent restricted stock units."}],"balance_after":147894,"source":{"system":"sec-edgar","filing":"0001628280-23-032065","document":"wk-form4_1694549085.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880179/000162828023032065/wk-form4_1694549085.xml","form_type":"4"}},{"id":1788823,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":74547,"kind":"person","name":"Arbet-Engels Christophe","position":1,"cik":"0001802615","reported_name":"Arbet-Engels Christophe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-05T20:15:36.000Z","date":"2023-08-31","kind":"grant","planned":false,"acquired":true,"shares":1250000,"price":1.28,"value":1600000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on August 31, 2024, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":1250000,"derivative":{"exercise_price":1.28,"expiration_date":"2033-08-30","underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001628280-23-031389","document":"wk-form4_1693944923.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023031389/wk-form4_1693944923.xml","form_type":"4"}},{"id":1799525,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-22T20:09:35.000Z","date":"2023-08-18","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.195,"value":29875.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at $1.195 and $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the shares of common stock reported, 48,333 shares represent restricted stock units."}],"balance_after":76667,"source":{"system":"sec-edgar","filing":"0001628280-23-030224","document":"wk-form4_1692734960.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000162828023030224/wk-form4_1692734960.xml","form_type":"4"}}],"next_cursor":"2023-08-22T20:09:35.000000Z,1799525"}